---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-24-000118"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:37:05.122657+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BeiGene appoints Shalini Sharp to Board of Directors effective September 27, 2024

## Summary
- Shalini Sharp, aged 49, appointed to fill vacancy on board expanded to 12 members.
- Former CFO of Ultragenyx Pharmaceuticals (2012-2020) and board member of Neurocrine Biosciences and Organon.
- Will receive equity awards valued at $400,000, annual cash compensation of $65,000 plus $17,500 for Audit Committee service.
- Appointment effective September 27, 2024; she will serve as Class III director until 2025 annual meeting.

## SEC filing metadata
- accession: 0001651308-24-000118
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000118/0001651308-24-000118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000118/bgne-20240925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-24-000118
- JSON: https://secwatch.observer/filing/0001651308-24-000118.json
- Plain text: https://secwatch.observer/filing/0001651308-24-000118.txt

## Key facts
- Executive change
  Shalini Sharp was appointed as Director at BeOne Medicines Ltd..
  - Action: appointed
  - Role: Director
  source text: appointed Shalini Sharp to the Board to fill the vacancy, effective September 27, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130824000118/0001651308-24-000118-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.